Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Luteal estradiol supplementation in gonadotropin-releasing hormone antagonist cycles for infertile patients in vitro fertilization

  • Kwon, Su-Kyoung (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Chung-Hoon (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Kyung-Hee (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jeon, Il Kyung (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Ahn, Jun-Woo (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Ulsan University Hospital, University of Ulsan College of Medicine) ;
  • Kim, Sung-Hoon (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Chae, Hee-Dong (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kang, Byung-Moon (Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2013.06.11
  • Accepted : 2013.08.02
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To evaluate the effect of the addition of estradiol to luteal progesterone supplementation in GnRH antagonist cycles for infertile patients undergoing IVF/ICSI. Methods: One hundred and ten infertile patients, aged 28 to 39 years, were recruited for this prospective randomized study. They were randomly assigned to receive vaginal progesterone gel (Crinone) along with 4 mg estradiol valerate (group 1, n=55) or only Crinone (group 2, n=55) for luteal support. A GnRH antagonist multiple dose protocol using recombinant human FSH was used for controlled ovarian stimulation (COS) in all of the subjects. The COS results and pregnancy outcomes of the two groups were compared. Results: Group 1 and 2 were comparable with respect to the patient characteristics. The COS and IVF results were also comparable between the two groups. There were no differences in the clinical pregnancy rate (PR) and multiple PR between the two groups. However, the embryo implantation rate were significantly higher in group 1 than that in group 2 (22.2% vs. 13.3%, p=0.035). The incidence of luteal vaginal bleeding (LVB) was significantly lower in group 1 (7.4% vs. 27.8%, p=0.010). Conclusion: The addition of estradiol to luteal progesterone supplementation in GnRH antagonist cycles reduces the incidence of LVB and increases the embryo implantation rate in infertile patients undergoing IVF/ICSI.

Keywords

References

  1. Tavaniotou A, Albano C, Smitz J, Devroey P. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. Hum Reprod 2001;16:663-7. https://doi.org/10.1093/humrep/16.4.663
  2. Sharara FI, McClamrock HD. Ratio of oestradiol concentration on the day of human chorionic gonadotrophin administration to mid-luteal oestradiol concentration is predictive of in-vitro fertilization outcome. Hum Reprod 1999;14:2777-82. https://doi.org/10.1093/humrep/14.11.2777
  3. Propst AM, Hill JA, Ginsburg ES, Hurwitz S, Politch J, Yanushpolsky EH. A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilizationembryo transfer cycles. Fertil Steril 2001;76:1144-9. https://doi.org/10.1016/S0015-0282(01)02872-2
  4. Engmann L, DiLuigi A, Schmidt D, Benadiva C, Maier D, Nulsen J. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertil Steril 2008;89:554-61. https://doi.org/10.1016/j.fertnstert.2007.04.006
  5. Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 2003;14:236-42. https://doi.org/10.1016/S1043-2760(03)00075-4
  6. Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 2002;17:2287-99. https://doi.org/10.1093/humrep/17.9.2287
  7. van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2011;(10):CD009154.
  8. Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein M. Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone--impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertil Steril 2011;95:617-20. https://doi.org/10.1016/j.fertnstert.2010.04.039
  9. Moini A, Zadeh Modarress S, Amirchaghmaghi E, Mirghavam N, Khafri S, Reza Akhoond M, et al. The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles: a randomized controlled study. Arch Med Sci 2011;7:112-6.
  10. Farhi J, Weissman A, Steinfeld Z, Shorer M, Nahum H, Levran D. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilizationembryo transfer cycles. Fertil Steril 2000;73:761-6. https://doi.org/10.1016/S0015-0282(99)00632-9
  11. Ghanem ME, Sadek EE, Elboghdady LA, Helal AS, Gamal A, Eldiasty A, et al. The effect of luteal phase support protocol on cycle outcome and luteal phase hormone profile in long agonist protocol intracytoplasmic sperm injection cycles: a randomized clinical trial. Fertil Steril 2009;92:486-93. https://doi.org/10.1016/j.fertnstert.2008.07.1717

Cited by

  1. British Fertility Society Policy and Practice Committee: Adjuvants in IVF: Evidence for good clinical practice vol.18, pp.1, 2013, https://doi.org/10.3109/14647273.2015.985454
  2. Luteal phase support with estradiol and progesterone versus progesterone alone in GnRH antagonist ICSI cycles: a randomized controlled study vol.19, pp.2, 2016, https://doi.org/10.1080/14647273.2016.1200145
  3. Estradiol use in the luteal phase and its effects on pregnancy rates in IVF cycles with GnRH antagonist: a systematic review vol.21, pp.3, 2013, https://doi.org/10.5935/1518-0557.20170046
  4. Estradiol Suppresses TLR4-triggered Apoptosis of Decidual Stromal Cells and Drives an Anti-inflammatory T H 2 Shift by Activating SGK1 vol.13, pp.4, 2013, https://doi.org/10.7150/ijbs.18278
  5. Plasmatic estradiol concentration in the mid-luteal phase is a good prognostic factor for clinical and ongoing pregnancies, during stimulated cycles of in vitro fertilization vol.22, pp.1, 2013, https://doi.org/10.5935/1518-0557.20180005
  6. Estrogel supplemontation in ART program vol.24, pp.5, 2013, https://doi.org/10.17116/repro20182405158
  7. Combined use of oestradiol and progesterone to support luteal phase in antagonist intracytoplasmic sperm injection cycles of normoresponder women: a case-control study vol.40, pp.2, 2013, https://doi.org/10.1080/01443615.2019.1631765
  8. Current Therapeutic Options for Controlled Ovarian Stimulation in Assisted Reproductive Technology vol.80, pp.10, 2020, https://doi.org/10.1007/s40265-020-01324-w